Current concepts in molecular genetics and management guidelines for pancreatic cystic neoplasms: an essential update for radiologists.
Abdom Radiol (NY). 2018 Sep;43(9):2351-2368. doi: 10.1007/s00261-017-1452-5.
Kulzer M1, Singhi AD2, Furlan A1, Heller MT1, Katabathina VS3, Mcgrath KM4, Zeh HJ5, Zureikat A5, Dasyam AK6.
Cystic neoplasms in the pancreas are encountered frequently on imaging, often detected incidentally during evaluation for other conditions. They can have a variety of clinical and imaging presentations, and similarly, wide-ranging prognostic and treatment implications. In the majority, imaging helps in diagnosis of pancreatic cystic neoplasms (PCNs) and guides management decisions. But, a significant minority of the PCNs remain indeterminate. There have been multiple recent advances in biomarkers and molecular genetics which will likely prove helpful in risk stratification of PCNs. Several prominent national and international societies, as well as consensus groups have put forth recommendations to help guide management of PCNs. The purpose of this article is to discuss the role of imaging in evaluation of PCNs, review the recent advances in molecular genetics and pancreatic cyst fluid analysis, and analyze the pros and cons of major evidence-based and consensus guidelines for management of PCNs.